OS Therapies Advances OST-HER2 Toward Phase 3 Trial
New York, March 27, 2026 OS Therapies has achieved a significant regulatory milestone by securing meetings with multiple global...
Phase 3 trial
Advertisement
Bristol Myers Squibb Reports New Camzyos Data at ACC
PRINCETON, NEW JERSEY, March 23, 2026 Bristol Myers Squibb has unveiled new clinical and real-world data for Camzyos (mavacamten)...
Daiichi Sankyo Expands ENHERTU Use in Japan
TOKYO, JAPAN, March 23, 2026 Daiichi Sankyo has announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved...
Sydnexis Reports Phase 3 STAR Data for SYD-101
Del Mar, California, USA | March 23, 2026 Sydnexis, Inc. has announced new Phase 3 clinical data from its...
Dizal Reports Phase 3 Breakthrough for ZEGFROVY in NSCLC
Shanghai, China | March 21, 2026 Dizal has announced positive topline results from its multinational Phase 3 WU-KONG28 clinical...
Advertisements
Innovent Doses First Patient in Phase 3 IBI128 Trial
San Francisco, USA / Suzhou, China | March 22, 2026 Innovent Biologics has announced that the first participant has...
Pfizer TALZENNA XTANDI Boost Survival in Prostate Cancer
NEW YORK, March 19, 2026 Pfizer Inc. announced that its Phase 3 TALAPRO-3 clinical trial evaluating TALZENNA® (talazoparib) in...
Novo Nordisk Wegovy HD Approved with 20% Weight Loss
BAGSVÆRD, Denmark, March 19, 2026 Novo Nordisk A/S announced that the U.S. Food and Drug Administration (FDA) has approved...
Shionogi Launches ZURZUVAE for Major Depression in Japan
OSAKA, Japan, March 19, 2026 Shionogi & Co., Ltd. has officially announced the commercial launch of ZURZUVAE® (zuranolone) 30...
AstraZeneca Imfinzi Wins EU Approval for Gastric Cancer
CAMBRIDGE, UK, March 16, 2026 AstraZeneca has received European Commission approval for Imfinzi (durvalumab) as the first and only...
Advertisement
